Description
Malegra-DXT is a medication that is used to treat erectile dysfunction and premature ejaculation in men. This medication is a combination of two active ingredients, duloxetine and sildenafil, which work together to help men achieve and maintain strong erections and delay ejaculation.
One of the main characteristics of Malegra-DXT is its active half-life, which lasts for approximately 4-5 hours. This means that the medication can provide effective results for up to 5 hours after taking the pill.
Malegra-DXT is classified as a serotonin-norepinephrine reuptake inhibitor (SNRI) and phosphodiesterase type 5 (PDE5) inhibitor. SNRIs work by increasing the levels of serotonin and norepinephrine in the brain, which can improve mood and reduce anxiety. PDE5 inhibitors like sildenafil work by increasing blood flow to the penis, which can help men achieve and maintain an erection.
The recommended dosage for Malegra-DXT is 130 mg per day for men. This dosage should not be exceeded, as it can increase the risk of side effects.
Unlike some other medications used to treat erectile dysfunction and premature ejaculation, Malegra-DXT does not typically cause acne or water retention. However, it is possible for some individuals to experience headaches, nausea, and other side effects.
Malegra-DXT should be used with caution in individuals with a history of heart disease, as it can increase the risk of heart attacks and other cardiovascular events. It is also important to note that Malegra-DXT may interact with other medications, so it is important to talk to a doctor before taking this medication.
Overall, Malegra-DXT is a safe and effective medication that can help men improve their sexual performance and quality of life. It is manufactured by Sunrise Remedies and is available in a pack of 10 pills, each containing 130 mg of the active substances duloxetine and sildenafil.
Sildenafil Citrate 100mg
Duloxetine 30mg
Anabolic activity index: not a steroid
Androgenic activity index: not a steroid
Reviews
There are no reviews yet.